Liquid Biopsy in Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 15830
Special Issue Editors
2. Nano-Biofluignostic Engineering Research Center, Korea University, 145 Anam-ro, Anam-dong, Seongbuk-gu, Seoul 136-701, Korea
Interests: liquid biopsy; cfDNA; exosome; cancer; virus; RCA
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the age of precision medicine, tumor nucleic acid characterization plays an important role in providing patients with the most appropriate diagnosis and treatment. The advancements in PCR and next-generation sequencing (NGS) paved the way for personalized medicine by enabling the genetic characteristics of tumors to be evaluated. The development of blood-based liquid biopsy technology is also at the center of the development of precision medicine. In particular, liquid biopsy has emerged as the gold standard for diagnosis and treatment following its FDA approval in 2016.
We are inviting innovative and original research papers focused on the development of various technologies for cancer diagnosis and monitoring using liquid biopsy, focusing on the experimental/laboratory and pre-clinical medicine aspects. The submission of review articles describing the latest technology on this topic are also encouraged.
Focusing on liquid biopsy, this Special Issue covers the use of circulating tumor DNA (ctDNA), circulating tumor cells (CTC), circulating tumor RNA (ctRNA), miRNA, and extracellular vesicles (EV).
Prof. Dr. Sehyun Shin
Dr. Kyong-Hwa Park
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- liquid biopsy
- ctDNA
- exosomes
- miRNA
- CTCs
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.